These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10798278)

  • 1. [Endothelium and endogenous fibrinolysis].
    Nordt TK; Bode C
    Z Kardiol; 2000 Mar; 89(3):219-26. PubMed ID: 10798278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin and vascular fibrinolytic balance.
    Vaughan DE
    Am J Hypertens; 2002 Jan; 15(1 Pt 2):3S-8S. PubMed ID: 11824873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease.
    Vaughan DE
    Eur Heart J; 1998 Jul; 19 Suppl G():G9-12. PubMed ID: 9717049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous NO regulates plasminogen activator inhibitor-1 during angiotensin-converting enzyme inhibition.
    Brown NJ; Muldowney JA; Vaughan DE
    Hypertension; 2006 Mar; 47(3):441-8. PubMed ID: 16432054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of vascular endothelial cells in the regulation of fibrinolysis.
    Grulich-Henn J; Müller-Berghaus G
    Z Kardiol; 1989; 78 Suppl 6():25-9. PubMed ID: 2694664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease.
    Agirbasli M
    Int J Clin Pract; 2005 Jan; 59(1):102-6. PubMed ID: 15707473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H; Sayiner ZA; Kilisli H
    Clin Exp Hypertens; 2012; 34(2):145-52. PubMed ID: 21967026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.
    Vaughan DE; Lazos SA; Tong K
    J Clin Invest; 1995 Mar; 95(3):995-1001. PubMed ID: 7884001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin, fibrinolysis, and vascular homeostasis.
    Vaughan DE
    Am J Cardiol; 2001 Apr; 87(8A):18C-24C. PubMed ID: 11334764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plasminogen activator inhibitor-1 (PAI-1), ischemic heart disease and diabetes mellitus].
    Olexa P; Olexová M
    Vnitr Lek; 2003 Mar; 49(3):222-6. PubMed ID: 12728597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinolytic system of cultured rabbit aortic endothelial cells.
    al-Azhary DB; Wojta J; Binder BR
    Thromb Res; 1994 Sep; 75(5):559-68. PubMed ID: 7992256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
    Brown NJ; Agirbasli M; Vaughan DE
    Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diminished fibrinolysis and thrombosis: clinical implications for accelerated atherosclerosis.
    Fujii S; Goto D; Zaman T; Ishimori N; Watano K; Kaneko T; Okada H; Makiguchi M; Nakagawa T; Kitabatake A
    J Atheroscler Thromb; 1998; 5(2):76-81. PubMed ID: 10855561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vascular wall renin-angiotensin system as a target of therapeutic interventions].
    Karpov IuA
    Kardiologiia; 2003; 43(5):82-6. PubMed ID: 12942932
    [No Abstract]   [Full Text] [Related]  

  • 16. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.
    Oikawa T; Freeman M; Lo W; Vaughan DE; Fogo A
    Kidney Int; 1997 Jan; 51(1):164-72. PubMed ID: 8995730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension.
    Sakata K; Pawlak R; Urano T; Takada A
    Pathophysiol Haemost Thromb; 2002; 32(2):67-75. PubMed ID: 12214151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents.
    Tsikouris JP; Suarez JA; Meyerrose GE
    J Clin Pharmacol; 2002 Nov; 42(11):1187-99. PubMed ID: 12412817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition.
    Vaughan DE
    Clin Cardiol; 1997 Nov; 20(11 Suppl 2):II-34-7. PubMed ID: 9422850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors.
    Sayer JW; Gutteridge C; Syndercombe-Court D; Wilkinson P; Timmis AD
    J Am Coll Cardiol; 1998 Dec; 32(7):1962-8. PubMed ID: 9857879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.